Confidential IPV Screening Tool
- Conditions
- Violence, Domestic
- Interventions
- Diagnostic Test: Screening for intimate partner violenceOther: Assessment and referral
- Registration Number
- NCT06284148
- Lead Sponsor
- Medical University of South Carolina
- Brief Summary
Intimate partner violence (IPV) against women in the US is a serious public health problem and a human rights issue. Our research team has developed confidential screening tools using exam-room computer for intimate partner violence to be used in primary care.
- Detailed Description
The objective of this study was to develop and evaluate an integrated suite of electronic health record (EHR) tools that automates "best practices" from Northern California Kaiser Permanente for screening and intervention for IPV identified within clinical settings. The goal of the intervention goes beyond mere screening of patients for IPV and includes tools for assessment of IPV risk, for documentation of IPV care, and support for a warm hand-off during the primary care visit to a national IPV hotline resource. Importantly, the study includes work to keep notes documenting IPV and billing for IPV care confidential, segmenting this care in a secure segment of the electronic health record.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 19655
- Being an Medical University of South Carolina patient at primary care clinics (family medicine)
- Women 18-49 years of age inclusive
- Reported yes to wanting to be contacted for a follow-up research study
- English-speaking
- No exclusion criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Sequence 2 Assessment and referral 5 clinics. Sequence 1 Assessment and referral 5 clinics. In stepped wedge design study, this was the sequence with shortest control (run-in) period. All sequences have a run-in period and intervention period. In control period participants were screened using existing nurse-led oral screening, in intervention period both - nurse-led and our new confidential screen were used at the same time. Sequence 2 Screening for intimate partner violence 5 clinics. Sequence 3 Screening for intimate partner violence 5 clinics. This was the sequence with longest control (run-in) period. Sequence 3 Assessment and referral 5 clinics. This was the sequence with longest control (run-in) period. Sequence 1 Screening for intimate partner violence 5 clinics. In stepped wedge design study, this was the sequence with shortest control (run-in) period. All sequences have a run-in period and intervention period. In control period participants were screened using existing nurse-led oral screening, in intervention period both - nurse-led and our new confidential screen were used at the same time.
- Primary Outcome Measures
Name Time Method Screening completed (Yes/No) 29 months Whether the assigned screening was completed during patient visit
IPV positive (Yes/No) 29 months Depending on patient's answers to screening questions, they are flagged as either IPV positive or negative
- Secondary Outcome Measures
Name Time Method Severity of risk 29 months using Danger 5 risk assessment, ranging from 0 to 5
Physician compliance with IPV management tools 29 months Measured as the rate of completion of follow-up decision templates, and the rate of referrals for post-visit counseling to a national hotline (a share from screened positive patients
Trial Locations
- Locations (1)
Biomedical Informatics Center
🇺🇸Charleston, South Carolina, United States